Literature DB >> 1976627

A novel transglutaminase-mediated post-translational modification of phospholipase A2 dramatically increases its catalytic activity.

E Cordella-Miele1, L Miele, A B Mukherjee.   

Abstract

Transglutaminases (TG), which include coagulation Factor XIIIa, are calcium-dependent ubiquitous enzymes. TGs catalyze the formation of an isopeptide bond by cross-linking a specific glutamine and a lysine residue between two proteins or within the same protein molecule. Phospholipase A2 (PLA2) is a key enzyme in the regulation of prostaglandin and leukotriene biosynthetic pathways, which catalyzes the release of free fatty acids from the sn-2 position of membrane glycerophospholipids. This enzyme has been suggested to be pathophysiologically related to the initiation and propagation of several inflammatory diseases including juvenile rheumatoid and rheumatoid arthritis. Here, we describe a novel TG-catalyzed post-translational modification of PLA2 which dramatically increases the activity of this enzyme. This increase was dependent upon the time of preincubation, the concentration of TG and the presence of Ca2+. Size exclusion chromatography of TG-treated PLA2 yielded two peaks of PLA2 activity, with apparent molecular masses of 26 and 13 kDa, respectively. The 26-kDa species, a putative PLA2 dimer, contained epsilon-(gamma-glutamyl)-lysine isopeptide in about 1:1 molar ratio to PLA2, suggesting an intramolecular rather than intermolecular cross-linking. This hypothesis was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the 26- and 13-kDa species under denaturing conditions. The specific activity of the dimeric peak was 10-fold higher with respect to that of the monomeric enzyme. These data suggest that TG-catalyzed covalent cross-linking of PLA2 is intramolecular and that this may promote a noncovalent dimerization and subsequent activation of this enzyme via a conformational change. To our knowledge, this is the first demonstration that TG-mediated post-translational modification of an enzyme (e.g. PLA2) causes a striking increase in the catalytic activity of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976627

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase.

Authors:  Lucio Miele
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides.

Authors:  P J Coussons; N C Price; S M Kelly; B Smith; L Sawyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

3.  Enzyme assays: Detection by failure.

Authors:  Nicholas A Melosh
Journal:  Nat Chem       Date:  2010-12       Impact factor: 24.427

Review 4.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

5.  Identification of a specific region of low molecular weight phospholipases A2 (residues 21-40) as a potential target for structure-based design of inhibitors of these enzymes.

Authors:  E Cordella-Miele; L Miele; A B Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.

Authors:  Dae Yong Kim; Bum Soo Park; Gwan Ui Hong; Byung Jae Lee; Jung Won Park; Soo Youl Kim; Jai Youl Ro
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

7.  Phospholipase A2 as a mechanosensor.

Authors:  J Y Lehtonen; P K Kinnunen
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

Review 8.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

9.  Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Authors:  Joonhong Sohn; Tae-Im Kim; Young-Hee Yoon; Joo-Yong Kim; Soo-Youl Kim
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 10.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.